Testing a universal method to measure certain blood thinner levels
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Nantes University Hospital · NCT04539301
This study is testing a new way to measure the levels of certain blood thinners in patients to help doctors manage their treatment better and keep them safe.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nantes University Hospital (other) |
| Locations | 1 site (Nantes, Loire-Atlantique) |
| Trial ID | NCT04539301 on ClinicalTrials.gov |
What this trial studies
This study aims to validate a universal test that can quantify the levels of four specific anticoagulants: apixaban, rivaroxaban, danaparoid, and fondaparinux. The researchers will utilize the widely used heparin anti-Xa assay to assess its effectiveness in measuring these anticoagulants, which are crucial for managing patients with conditions like venous thromboembolism and atrial fibrillation. By analyzing blood samples from adult patients treated with these medications, the study seeks to improve monitoring and safety in anticoagulation therapy.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients currently being treated with apixaban, rivaroxaban, danaparoid, or fondaparinux.
Not a fit: Patients receiving unfractionated heparin or low molecular weight heparin will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to monitor anticoagulant therapy, leading to better patient outcomes and reduced complications.
How similar studies have performed: While specific studies on this universal testing approach are limited, the use of anti-Xa assays for heparin has been well-established, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria : * Blood sample from adult patients treated with apixaban or rivaroxaban or danaparoid or fondaparinux Exclusion Criteria : * Patients treated with unfractionated heparin or low molecular weight heparin
Where this trial is running
Nantes, Loire-Atlantique
- Nantes University Hospital — Nantes, Loire-Atlantique, France (RECRUITING)
Study contacts
- Study coordinator: Elodie BOISSIER
- Email: elodie.boissier@chu-nantes.fr
- Phone: 330240165465
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Anticoagulation, Venous Thromboembolism, Atrial Fibrillation, Anticoagulants, Blood Coagulation Tests, Drug monitoring, Factor Xa Inhibitors, Heparin